FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 460 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL July 29, 2021 Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 Making Important Decisions During Cancer: A Survivor’s Story October 26, 2021 Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... May 3, 2022 Load more HOT NEWS Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial... Body Location May Influence Fate of Cells with Cancer-Causing Mutations 35-Year-Old Mom Has Been Living With Stage IV Breast Cancer For... Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A
